OTCMKTS:ATRX

Adhera Therapeutics Stock Forecast, Price & News

$0.08
0.00 (0.00 %)
(As of 04/14/2021 01:55 PM ET)
Add
Compare
Today's Range
$0.08
Now: $0.08▼
$0.08
50-Day Range
$0.08
MA: $0.10▼
$0.13
52-Week Range
$0.02
Now: $0.08▼
$0.30
Volume34,245 shs
Average Volume40,587 shs
Market Capitalization$872,325.00
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Adhera Therapeutics, Inc. does not have significant operations. Previously, it was involved in the development and commercialization of drug therapeutics for chronic and acute diseases in the United States. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is headquartered in Wake Forest, North Carolina.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ATRX
Previous Symbol
CUSIPN/A
CIKN/A
Webadherathera.com
Phone919-518-3748
Employees2
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$250,000.00
Price / Sales3.49
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.91) per share
Price / Book-0.08

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-11,980,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-3,131.56%

Miscellaneous

Outstanding Shares11,631,000
Market Cap$872,325.00
Next Earnings DateN/A
OptionableNot Optionable

Headlines

Adhera Therapeutics, Inc. (OTCMKTS:ATRX) Sees Large Drop in Short Interest
March 27, 2021 |  americanbankingnews.com
Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock
September 21, 2020 |  finance.yahoo.com
Adhera Therapeutics Announces Third Quarter 2019 Financial Results and Operational Highlights
September 21, 2020 |  finance.yahoo.com
See More Headlines

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Medical Sector

1974th out of 2,019 stocks

Pharmaceutical Preparations Industry

765th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.08
0.00 (0.00 %)
(As of 04/14/2021 01:55 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adhera Therapeutics (OTCMKTS:ATRX) Frequently Asked Questions

What stocks does MarketBeat like better than Adhera Therapeutics?

Wall Street analysts have given Adhera Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adhera Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Adhera Therapeutics?

Adhera Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 1,000 shares, a drop of 96.0% from the February 28th total of 25,100 shares. Based on an average daily volume of 32,000 shares, the short-interest ratio is currently 0.0 days.
View Adhera Therapeutics' Short Interest.

Who are Adhera Therapeutics' key executives?

Adhera Therapeutics' management team includes the following people:
  • Mr. Andrew Albert Kucharchuk, CEO & Director (Age 40)
  • Dr. Peter D. Weinstein Ph.D., J.D., Chief Legal Officer (Age 58)
  • Dr. Seymore Howard Fein, Chief Medical Officer (Age 72)
  • Mr. Jay D. Schwartz, Sr. VP of Commercial Operations

Who are some of Adhera Therapeutics' key competitors?

Some companies that are related to Adhera Therapeutics include VG Life Sciences (VGLS), RespireRx Pharmaceuticals (RSPI), Immune Pharmaceuticals (IMNPQ), Innovus Pharmaceuticals (INNVD), Inspyr Therapeutics (NSPX), Boston Therapeutics (BTHE), VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUCD), Capstone Therapeutics (CAPS), W World (WWHC), Earth Science Tech (ETST), ImmunoCellular Therapeutics (IMUC), Cardax (CDXI), Melinta Therapeutics (MLNTQ) and Achaogen (AKAOQ).
View all of ATRX's competitors.

What other stocks do shareholders of Adhera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced Biomedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

What is Adhera Therapeutics' stock symbol?

Adhera Therapeutics trades on the OTCMKTS under the ticker symbol "ATRX."

How do I buy shares of Adhera Therapeutics?

Shares of ATRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adhera Therapeutics' stock price today?

One share of ATRX stock can currently be purchased for approximately $0.08.

How much money does Adhera Therapeutics make?

Adhera Therapeutics has a market capitalization of $872,325.00 and generates $250,000.00 in revenue each year.

How many employees does Adhera Therapeutics have?

Adhera Therapeutics employs 2 workers across the globe.

What is Adhera Therapeutics' official website?

The official website for Adhera Therapeutics is adherathera.com.

Where are Adhera Therapeutics' headquarters?

Adhera Therapeutics is headquartered at P.O. BOX 2161, WAKE FOREST NC, 27588.

How can I contact Adhera Therapeutics?

Adhera Therapeutics' mailing address is P.O. BOX 2161, WAKE FOREST NC, 27588. The company can be reached via phone at 919-518-3748 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.